Jazz Pharmaceuticals plc (JAZZ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 500M 1B 1.5B Q3 '21: 838.1M Q4 '21: 896.7M Q1 '22: 813.7M Q2 '22: 932.9M Q3 '22: 940.7M Q4 '22: 972.1M Q1 '23: 892.8M Q2 '23: 957.3M Q3 '23: 972.1M Q4 '23: 1B Q1 '24: 902M Q2 '24: 1B Q3 '24: 1.1B Q4 '24: 1.1B Q1 '25: 897.8M Q2 '25: 1B Q3 '25: 1.1B Q4 '25: 1.2B Q1 '26: 1.1B Q2 '26: 1.2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 250M 500M 750M Q1 '16: 310.5M Q2 '16: 355.1M Q3 '16: 347.3M Q4 '16: 359M Q1 '17: 348.6M Q2 '17: 361M Q3 '17: 376.8M Q4 '17: 404.8M Q1 '18: 406.9M Q2 '18: 461.4M Q3 '18: 438.6M Q4 '18: 441M Q1 '19: 469.8M Q2 '19: 495.7M Q3 '19: 500.9M Q4 '19: 541.2M Q1 '20: 501.5M Q2 '20: 530.2M Q3 '20: 554.9M Q4 '20: 611.1M Q2 '16 Q1 '17 Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '20

Operating Income Quarterly

-750M -500M -250M 0 250M 500M 750M Q1 '21: 162.1M Q2 '21: -69.6M Q3 '21: 28.4M Q4 '21: 49.4M Q1 '22: 87.5M Q2 '22: 85.5M Q3 '22: 24.8M Q1 '23: 126.1M Q2 '23: 157.6M Q3 '23: 172.4M Q4 '23: 122.5M Q1 '24: 66.2M Q2 '24: 199.4M Q3 '24: 260.2M Q4 '24: 190.8M Q1 '25: -55.9M Q2 '25: -686.4M Q3 '25: 57.5M Q1 '26: 336.6M Q2 '26: 248.2M Q2 '21 Q1 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Net Income Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '21: -52.8M Q4 '21: -35.4M Q1 '22: 1.6M Q2 '22: 34.7M Q3 '22: -19.6M Q4 '22: -240.7M Q1 '23: 69.4M Q2 '23: 104.4M Q3 '23: 146.8M Q4 '23: 94.2M Q1 '24: -14.6M Q2 '24: 168.6M Q3 '24: 215.1M Q4 '24: 191.1M Q1 '25: -92.5M Q2 '25: -718.5M Q3 '25: 251.4M Q4 '25: 203.4M Q1 '26: 293.1M Q2 '26: 192.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

0 200M 400M 600M Q3 '21: 274.1M Q4 '21: 177.8M Q1 '22: 209M Q2 '22: 303M Q3 '22: 418M Q4 '22: 342M Q1 '23: 320.7M Q2 '23: 296.8M Q3 '23: 307.2M Q4 '23: 167.3M Q1 '24: 267.2M Q2 '24: 331.4M Q3 '24: 398.7M Q4 '24: 398.6M Q1 '25: 429.8M Q2 '25: 88.8M Q3 '25: 474.7M Q4 '25: 362.5M Q1 '26: 408.2M Q2 '26: 415.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

0 200M 400M 600M Q3 '21: 265.7M Q4 '21: 167.8M Q1 '22: 196.7M Q2 '22: 290.8M Q3 '22: 413.1M Q4 '22: 332.6M Q1 '23: 316.9M Q2 '23: 291M Q3 '23: 302.9M Q4 '23: 157.2M Q1 '24: 260.3M Q2 '24: 324.3M Q3 '24: 388M Q4 '24: 385.3M Q1 '25: 415.9M Q2 '25: 75.9M Q3 '25: 459.4M Q4 '25: 345.8M Q1 '26: 388.5M Q2 '26: 397.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '20: 56M Q2 '20: 55.9M Q3 '20: 56.2M Q1 '21: 58.4M Q2 '21: 59.4M Q3 '21: 61.3M Q1 '22: 62.9M Q2 '22: 63.4M Q3 '22: 62.8M Q1 '23: 73.8M Q2 '23: 73.5M Q3 '23: 71.3M Q1 '24: 62.5M Q2 '24: 69.6M Q3 '24: 63.2M Q1 '25: 61M Q2 '25: 61.2M Q3 '25: 61.6M Q1 '26: 66.1M Q2 '26: 69.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -2.55 Q4 '21: -5.42 Q1 '22: -7.48 Q2 '22: -0.82 Q3 '22: -0.27 Q4 '22: -3.57 Q1 '23: -2.56 Q2 '23: -1.59 Q3 '23: 0.86 Q4 '23: 6.13 Q1 '24: 4.86 Q2 '24: 5.83 Q3 '24: 7.11 Q4 '24: 8.70 Q1 '25: 7.41 Q2 '25: -6.82 Q3 '25: -6.16 Q4 '25: -5.84 Q1 '26: 0.11 Q2 '26: 14.63 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.